VERU INC. 10-Q Filing Summary
Business Context and Reporting Period
Company: VERU INC. (VERU)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2025
Business Overview: Veru is a late clinical-stage biopharmaceutical company focused on cardiometabolic and inflammatory diseases. Its primary drug candidates are enobosarm (for obesity/muscle preservation) and sabizabulin (for atherosclerosis). The company sold its commercial FC2 business on December 30, 2024, and previously sold ENTADFI assets in 2023. As of the filing date, the company has no commercial revenue.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2025 | Six Months Ended Mar 31, 2025 | As of Mar 31, 2025 |
|---|---|---|---|
| Net Loss (Continuing Ops) | $(7.85) million | $(9.66) million | N/A |
| Net Loss (Total) | $(7.90) million | $(16.85) million | N/A |
| Net Loss Per Share (Basic/Diluted) | $(0.05) | $(0.12) | N/A |
| Operating Expenses | $9.10 million | $20.04 million | N/A |
| Research & Development | $3.93 million | $9.65 million | N/A |
| Cash & Equivalents | N/A | N/A | $20.02 million |
| Working Capital | N/A | N/A | $15.76 million |
| Stockholders' Equity | N/A | N/A | $21.05 million |
Note: Revenue from continuing operations is $0. Discontinued operations (FC2) generated $0 revenue in Q2 2025.
Material Changes vs. Prior Period
- FC2 Business Sale: The company sold its FC2 business on December 30, 2024. This resulted in a $4.2 million loss on sale recorded in discontinued operations for the six months ended March 31, 2025. Consequently, there are no assets or liabilities of discontinued operations on the March 31, 2025 balance sheet.
- Debt Extinguishment: In connection with the FC2 sale, the company made a $4.2 million change-of-control payment to terminate the Residual Royalty Agreement. This resulted in a non-operating gain on extinguishment of debt of $8.6 million for the six-month period.
- Operating Expenses: R&D expenses increased to $9.65 million (six months 2025) from $4.64 million (six months 2024), driven by the Phase 2b QUALITY clinical trial for enobosarm. SG&A expenses decreased to $10.39 million from $12.56 million, primarily due to reduced share-based compensation.
- ENTADFI Gain: The company recognized a gain of $1.67 million on the sale of ENTADFI assets for the six months ended March 31, 2025, as non-refundable consideration was received.
Guidance, Outlook, and Risks
- Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for twelve months following the issuance date. Cash on hand ($20.0 million) is insufficient to fund operations for the next year without additional financing.
- Enobosarm (Obesity Program): Positive topline results were announced on January 27, 2025, from the Phase 2b QUALITY trial. Enobosarm significantly preserved lean mass and reduced fat loss in patients taking semaglutide. The company plans to request an End of Phase 2 meeting with the FDA and propose a Phase 3 clinical program.
- Sabizabulin (Cardiovascular Program): The company is exploring development for atherosclerosis. A Phase 2 study is planned for 2026, contingent on funding and FDA acceptance of the trial design.
- Capital Needs: The company expects to finance future needs through public/private equity offerings or debt. No specific guidance on future capital raise amounts was provided.
- Legal & Contingencies:
- Shareholder Litigation: Multiple class action and derivative lawsuits are pending regarding prior statements about sabizabulin. Potential losses cannot be estimated.
- ONCO Receivables: The company holds promissory notes from Onconetix (ONCO) for the ENTADFI sale. ONCO has defaulted on payments, and a Forbearance Agreement is in place. Collectability is uncertain.
- Supplier Dispute: A resolved dispute requires the company to pay $8.3 million to a supplier, with significant portions due in installments through 2028.
- Nasdaq Listing: The company received a notice of delisting due to the stock price falling below $1.00. An extension was granted until August 25, 2025, to regain compliance, potentially via a reverse stock split.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline for the next capital raise given the "substantial doubt" going concern warning and current cash burn rate.
- ONCO Collectability: Assess the likelihood of recovering the remaining principal on the ONCO promissory notes given the borrower's financial status and the terms of the Forbearance Agreement.
- FC2 Sale Adjustments: Monitor the resolution of the working capital dispute regarding the FC2 Business Sale, which could adjust the final proceeds.
- Phase 3 Funding: Confirm the estimated cost of the proposed Phase 3 enobosarm trial and whether current cash reserves or existing financing agreements cover it.
- Nasdaq Compliance: Track the stock price relative to the $1.00 threshold and the company's progress toward shareholder approval for a potential reverse stock split.